MUMBAI: Indian biotech frontrunner Biocon and its global partner for biosimilars, Mylan, have announced positive data from phase 3 clinical trials of a proposed copy of trastuzumab, a complex injection used widely to treat a type of breast cancer.
The trial results, being presented this week at the American Society of Clinical Oncology - a prestigious conference held annually in the US —gives the drugmakers an edge over rivals and will enable regulatory submissions for commercial la ..
The trial results, being presented this week at the American Society of Clinical Oncology - a prestigious conference held annually in the US —gives the drugmakers an edge over rivals and will enable regulatory submissions for commercial la ..
No comments:
Post a Comment